Key Highlights
- PROCEPT BioRobotics shares fell 8.59% pre-market today to $19.80, from a prior close of $21.66.
- Third-quarter Revenue rose 18% to $98.3 million, about $2.2 million below the consensus estimate.
- The loss of $0.46 per share compared with an expected loss of $0.39.
- U.S. procedures grew 22% to more than 13,400, while U.S. system revenue was flat.
- 2026 revenue guidance of $390 million to $410 million was held, with procedures guided near the low end of the range.
PROCEPT BioRobotics (NASDAQ:PRCT) shares came under pressure in pre-market activity today after third-quarter results missed estimates on both revenue and earnings, even though the company reaffirmed its 2026 guidance. The stock changed hands at $19.80, down 8.59% from Wednesday's close of $21.66, which followed a 7.39% gain in the regular session.
PROCEPT is a San Jose, California-based commercial-stage surgical robotics company focused on urology and the treatment of benign prostatic hyperplasia. Its AquaBeam and next-generation, AI-enabled HYDROS Robotic Systems deliver Aquablation therapy, an image-guided, heat-free robotic waterjet procedure that removes prostate tissue. Hospitals and surgery centers buy the Capital system, and PROCEPT earns Recurring Revenue from single-use handpieces and service contracts.
Management said new-account placements were slower than expected and guided full-year procedures to about 54,000, the low end of its range.
Greenfield Placements Fall Short as Shipping Timing Weighs on Systems
Third-quarter revenue reached $98.3 million, up 18% from a year earlier, against an expected $100.5 million. U.S. revenue was $85.8 million, up 16%, and record international revenue was $12.5 million, up 32%. More than 13,400 U.S. procedures were completed, up 22%,.
The company shipped 62 HYDROS systems at an average selling price near $495,000, including 20 replacements, or 36 year to date. Greenfield placements fell short because of shipping timing, and three shipped systems had revenue deferred until payment, which is expected in the fourth quarter. HYDROS accounts ran more than 35% higher in procedure Volume than legacy AquaBeam accounts, and the shift of surgeons from AquaBeam to HYDROS was the biggest utilization headwind.
Wider Loss Meets a Reaffirmed Full-Year Revenue Range
Gross Margin was 66%, operating expenses were $92.5 million, and the net loss was $26.5 million. Adjusted EBITDA was a loss of $9.8 million. Cash stood at $221.4 million.
Full-year revenue guidance remains $390 million to $410 million, or 27% to 33% growth, with international revenue of $50 million to $51 million and procedures near 54,000 within a 54,000 to 56,000 range. Operating expenses are now expected at $359 million to $363 million, and the adjusted EBITDA loss at $30 million to $35 million. Fourth-quarter gross margin is expected near 65%, with adjusted EBITDA of positive $3 million to $9 million.
PROCEPT carries a market Capitalization of about $1.23 billion, and its 52-week range runs from $16.67 to $38.11.
Replacement Sales and a 20% Growth Base Case Frame the Next Update
Management expects 50 to 60 replacement sales at about $315,000 each and a surpassing of initial system revenue guidance. For 2027, about 20% revenue growth is the base case, assuming similar capital, stable pricing, international near 25% of revenue and no benefit from prostate cancer. Gross margin is expected to expand by 100 to 200 basis points, and HYDROS should exceed 60% of the installed base by year-end.
The next signals are whether greenfield placements recover and the deferred revenue is collected. Data from the WATER IV prostate cancer study is due at the American Urological Association meeting in May 2027.






Please wait processing your request...